Skip to main content

Table 1 Characteristics of patients in the whole cohort

From: The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study

  Total Major-responders Non-responders P
N = 248 N = 102 N = 146
Age (year, mean ± SD) 54.61 ± 11.61 54.20 ± 11.17 55.20 ± 12.25 0.514
Sex     0.548
 Male 176 (71.0%) 101 (69.2%) 75 (73.5%)  
 Female 72 (29.0%) 45 (30.8%) 27 (26.5%)  
Histopathological type     0.793
 Adenocarcinoma 236 (95.2%) 138 (94.5%) 98 (96.1%)  
 Mucinous adenocarcinoma 12 (4.8%) 8 (5.5%) 4 (3.9%)  
Differentiation grade     0.274
 Well or moderate 232 (93.5%) 134 (91.8%) 98 (96.1%)  
 Poor 16 (6.5%) 12 (8.2%) 4 (3.9%)  
cT status     0.657
 cT2 10 (4.0%) 6 (4.1%) 4 (4.0%)  
 cT3 175 (70.6%) 106 (72.6%) 69 (67.6%)  
 cT4 63 (25.4%) 34 (23.3%) 29 (28.4%)  
cN status     0.07
 cN0 38 (15.3%) 19 (13.0%) 19 (18.6%)  
 cN1 101 (40.7%) 54 (37.0%) 47 (46.1%)  
 cN2 109 (44.0%) 73 (50.0%) 36 (35.3%)  
Tumour location     0.787
 < 5 cm 140 (56.5%) 85 (58.2%) 55 (53.9%)  
 5–10 cm 103 (41.5%) 58 (39.7%) 45 (44.1%)  
 > 10 cm 5 (2.0%) 3 (2.1%) 2 (2.0%)  
CEA level     0.731
 Normal 143 (57.7%) 86 (58.9%) 57 (55.9%)  
 Abnormal 105 (42.3%) 60 (41.1%) 45 (44.1%)  
CA199 level     0.550
 Normal 196 (79.0%) 113 (77.4%) 83 (81.4%)  
 Abnormal 52 (21.0%) 33 (22.6%) 19 (18.6%)  
Chemotherapeutic regimen     0.001
 5-fluorouracil 35 (14.1%) 16 (11.0%) 19 (18.6%)  
 Capecitabine 33 (13.3%) 10 (6.8%) 23 (22.5%)  
 FOLFOX 150 (60.5%) 104 (71.2%) 46 (45.1%)  
 Other regimens 30 (12.1%) 16 (11.0%) 14 (81.4%)  
Time interval between nCRT and surgery     0.046
 < 7 weeks 13 (5.3%) 4 (2.8%) 9 (8.8%)  
 7–10 weeks 91 (36.8%) 50 (34.5%) 41 (40.2%)  
 > 10 weeks 143 (57.9%) 91 (62.8%) 52 (51.0%)  
Neoadjuvant radiotherapy dose     0.012
 < 45 Gy 20 (8.1%) 6 (4.1%) 14 (13.7%)  
 ≥ 45 Gy 228 (91.9%) 140 (95.9%) 88 (86.3%)